San Francisco ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs and cells implicated in disease, enabling improved efficacy and potency.
Recode Tx has a pipeline of rare disease therapeutics and is planning to initiate their first clinical trials in the EU in 2024. In particular, Recode Tx are exploring EU sites for the conduct of a Phase 1 study to evaluate their mRNA-based LNP therapy for patients with Primary Ciliary Dyskinesia caused by mutations in the DNAI1 gene. With Denmark being home to one of the leading researchers in the field, Professor Kim G. Nielsen from Copenhagen University hospital (Rigshospitalet), it made sense for ReCode Tx to partner closely with Dr. Nielsen to design a trial for PCD patients with mutations in the DNAI1 mutation that could begin Europe.
As the company were preparing the study protocol, they were looking at an opportunity to consult with the Clinical Trials Unit at the Danish Medicines Agency (DKMA).